Shandong Lukang Pharmaceutical Co Ltd (600789) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Shandong Lukang Pharmaceutical Co Ltd stock ¥2.72, price ¥7.09, that is 61.6% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥5.17 – ¥11.70 · fair‑value band ¥2.68 – ¥2.85 · the ¥7.09 price screens above the ¥2.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Shandong Lukang Pharmaceutical Co in your weekly email
Every Wednesday you see whether Shandong Lukang Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products.
Show moreShow less
It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its products to European Union, the United States, the United Kingdom, Russia, India, Brazil, Japan, and internationally.
The company was formerly known as Jining Antibiotic Factory and changed its name to Shandong Lukang Pharmaceutical Co.,Ltd. in October 1993. Shandong Lukang Pharmaceutical Co.,Ltd. was founded in 1966 and is headquartered in Jining, China.
Stock analysis
Shandong Lukang Pharmaceutical Co Ltd (600789) currently trades at ¥7.09, while our model-based Fair Value estimate is ¥2.72, 62% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥6.67 per share, and 6 of the 26 models we run sit above the ¥7.09 price.
Bear case: the Growth Earnings group reads lowest at ¥1.79, and 20 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥2.68 (bear) to ¥2.85 (bull), the price of ¥7.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 1998: revenue and profit before it include the divested business. Growth is measured afresh from 1998.
Shandong Lukang Pharmaceutical Co Ltd reported revenue of 5.8B CNY in FY2025 versus 4.9B CNY in FY2021, a compound +4.0%/yr. Reported net income was 112M CNY in FY2025, compounding +6.0%/yr from FY2021.
Key figures
Market cap 7.4B CNY (≈ $1.1B) Small · P/E ratio 54.5 · P/S ratio 1.27 · EPS (TTM) ¥0.1300 · Dividend yield 0.7% · Net margin 2.5% · Return on equity 3.1% · Return on assets (EBIT) 2.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (medium confidence).
What moves the price
The share trades about 34% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −62%, 600789 screens richer than that median.
Fair Value models
Bear¥2.68Fair Value ¥2.72Bull¥2.85
Price ¥7.09 · Downside -61.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0686 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥5.36¥7.69¥11.0980
Growth DCF¥5.36¥7.54¥10.6179
Owner Earnings¥4.13¥5.77¥8.1677
All 26 models by family
DCF Models
FCF DCF¥5.36¥7.69¥11.0980
Owner Earnings¥4.13¥5.77¥8.1677
5Y Revenue Exit¥4.19¥5.78¥7.8073
5Y EBITDA Exit¥6.84¥10.92¥15.8475
5Y P/E Exit¥3.75¥4.92¥6.1472
10Y Revenue Exit¥4.53¥6.07¥8.1667
10Y EBITDA Exit¥6.21¥9.49¥14.1368
10Y P/E Exit¥4.33¥5.50¥6.9365
Earnings-Based
Graham-Dodd¥0.7300¥2.73¥3.6864
Lynch FV¥0.6600¥0.9400¥1.2261
PEG = 1.0¥0.6600¥0.9400¥1.2257
EPV¥3.19¥3.47¥3.7174
Dividend Discount
Gordon GGM¥1.29¥2.41¥3.4367
DDM Multi-Stage¥1.29¥2.16¥2.5767
Multiples
P/E Multiple¥1.77¥2.36¥2.9563
P/S Multiple¥1.37¥1.83¥2.2858
P/B Multiple¥7.44¥9.92¥12.4055
EV/EBIT¥1.64¥2.76¥3.8864
EV/EBITDA¥5.56¥7.99¥10.4167
EV/Revenue¥0.6800¥1.71¥2.7350
Asset-Based
NCAV (Graham)¥0.0200¥0.0300¥0.040054
Growth DCF
Growth DCF¥5.36¥7.54¥10.6179
Rev-Margin DCF¥4.19¥5.80¥7.7673
Economic Profit
Residual Income¥3.15¥3.20¥3.3576
ROIC Compounder¥3.19¥3.47¥3.7172
Growth Earnings
Growth-Adj P/E¥1.25¥1.79¥2.3267
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 1998: revenue and profit before it include the divested business. Growth is measured afresh from 1998.
Revenue growth 1 year
−7.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Start year 2020 (pandemic). Over 10 years: +9.1% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+12.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.7%
Dividend (yield on the price)0.7%
Per share before 1998divided by the spin-off factor 1.0368
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.8% vs 16.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 5%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +13.3% a year for the price.
Compare Shandong Lukang Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside−61.6% · Bottom 25%
Profitability
Return on equity (12 months)3.1% · Below median
Return on assets1.1% · Below median
Net margin (12 months)2.5% · Below median
Operating margin (12 months)4.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)9.5% · Above median
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.21× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)54.5× · Priciest 25%
P/B1.45× · Cheaper than median
P/S (12 months)1.27× · Cheaper than median
Price / free cash flow (fiscal year)20.6× · Pricier than median
EV/EBITDA9.6× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)48· sector 25
PAST (return on equity)12· sector 29
HEALTH (low debt)89· sector 96
DIVIDEND (yield)14· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shandong Lukang Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600789
Frequently asked questions
Is Shandong Lukang Pharmaceutical Co Ltd (600789) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥2.72 versus a price of ¥7.09, about 62% lower (overvalued).
What is the fair value of 600789?
Our model-based fair value for Shandong Lukang Pharmaceutical Co Ltd is ¥2.72 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥7.09.
What is the quality score of 600789?
Shandong Lukang Pharmaceutical Co Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Lukang Pharmaceutical Co Ltd (600789)?
Our model-based price target is the fair value of ¥2.72 (as of Nov 7, 2026) from 26 valuation models. Cautious scenario ¥2.68, optimistic scenario ¥2.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Lukang Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥2.72, about 62% lower versus a price of ¥7.09 (overvalued). Cautious scenario ¥2.68, optimistic scenario ¥2.85. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Lukang Pharmaceutical Co Ltd (600789)?
Shandong Lukang Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 5.8B CNY (latest available figure, as of Nov 7, 2026).
Does Shandong Lukang Pharmaceutical Co Ltd pay a dividend?
Shandong Lukang Pharmaceutical Co Ltd currently shows a dividend yield of 0.71% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Shandong Lukang Pharmaceutical Co Ltd (600789) and when is the ex-dividend date?
Shandong Lukang Pharmaceutical Co Ltd pays a dividend of ¥0.05 per share a year, a dividend yield of 0.7%. The last ex-dividend date was Jul 15, 2026. The payout ratio is 38.5% of earnings. Free cash flow covers the dividend 6.88 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Shandong Lukang Pharmaceutical Co Ltd (600789)?
For today's price to be fair in a discounted-cash-flow model, Shandong Lukang Pharmaceutical Co Ltd would have to grow free cash flow by +15.2 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.5 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 600789 use?
Our models discount Shandong Lukang Pharmaceutical Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.23, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shandong Lukang Pharmaceutical Co Ltd that is +15.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Shandong Lukang Pharmaceutical Co Ltd (600789) delivered so far?
Over the past 5 years revenue at Shandong Lukang Pharmaceutical Co Ltd grew +6.5 % a year. The price currently implies free-cash-flow growth of +15.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shandong Lukang Pharmaceutical Co Ltd (600789) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Shandong Lukang Pharmaceutical Co Ltd (+15.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The free-cash-flow yield on the price is 4.85 %: that much free cash flow Shandong Lukang Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shandong Lukang Pharmaceutical Co Ltd (600789)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Lukang Pharmaceutical Co Ltd it is ¥2.72 per share (as of Nov 7, 2026), against a price of ¥7.09. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shandong Lukang Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 600789 trades above its calculated fair value: price ¥7.09, fair value ¥2.72, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600789?
No. The price is what the market pays today (¥7.09); the fair value is what the company's own numbers justify (¥2.72). For Shandong Lukang Pharmaceutical Co Ltd the two are ¥4.37 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Lukang Pharmaceutical Co Ltd worth?
The market values Shandong Lukang Pharmaceutical Co Ltd at about 7.4B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥7.09; our models calculate a fair value of ¥2.72 per share.
What do the bullish and bearish scenarios say about 600789?
Our models span a range for Shandong Lukang Pharmaceutical Co Ltd: cautious scenario ¥2.68, base ¥2.72, optimistic ¥2.85 per share (as of Nov 7, 2026, price ¥7.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 600789?
Shandong Lukang Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 54.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥2.72 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 48.4. Other multiples: P/B 1.5, P/S 1.3, EV/EBITDA 9.6.
How solid is the balance sheet of Shandong Lukang Pharmaceutical Co Ltd (600789)?
Balance-sheet figures for Shandong Lukang Pharmaceutical Co Ltd (as of Nov 7, 2026): return on equity 3.1%, debt of 0.21 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 600789 from its 52-week high?
Shandong Lukang Pharmaceutical Co Ltd trades at ¥7.09, about 34% below its 52-week high of ¥10.71 and 6% above the low of ¥6.71 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.72 is for.
Which stocks are comparable to Shandong Lukang Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Lukang Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ¥7.09, calculated fair value ¥2.72 (−62%), Quality Score 37/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600789 calculated?
We run Shandong Lukang Pharmaceutical Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥2.72 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shandong Lukang Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The closing price on Nov 9, 2026 was ¥7.09. Our model-based fair value is ¥2.72, about 62% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Lukang Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥2.85). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (¥2.68 to ¥2.85), unusually little disagreement for a valuation.
Key figures of Shandong Lukang Pharmaceutical Co Ltd
How large is the market capitalisation of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The market capitalisation of Shandong Lukang Pharmaceutical Co Ltd is 7.4B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The price-to-sales ratio of Shandong Lukang Pharmaceutical Co Ltd is 1.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shandong Lukang Pharmaceutical Co Ltd (600789)?
Earnings per share at Shandong Lukang Pharmaceutical Co Ltd are ¥0.1300 (price ÷ EPS = P/E 54.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The dividend yield of Shandong Lukang Pharmaceutical Co Ltd is 0.7% (payout 38.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The net margin of Shandong Lukang Pharmaceutical Co Ltd is 2.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The return on equity (ROE) of Shandong Lukang Pharmaceutical Co Ltd is 3.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Lukang Pharmaceutical Co Ltd (600789)?
On an EBIT basis the return on assets of Shandong Lukang Pharmaceutical Co Ltd is 2.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Lukang Pharmaceutical Co Ltd (600789)?
The operating margin of Shandong Lukang Pharmaceutical Co Ltd is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Lukang Pharmaceutical Co Ltd (600789)?
Revenue at Shandong Lukang Pharmaceutical Co Ltd is growing +9.5% versus a year earlier (3y avg +0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Lukang Pharmaceutical Co Ltd (600789)?
Earnings per share at Shandong Lukang Pharmaceutical Co Ltd are growing +157% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Shandong Lukang Pharmaceutical Co Ltd (600789) carry?
The net debt of Shandong Lukang Pharmaceutical Co Ltd is 1.8B CNY (fiscal year 2024, ≈ 5.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shandong Lukang Pharmaceutical Co Ltd in the live analysis
One click puts Shandong Lukang Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026